Hyperglycemia is treated through a layered approach that typically begins with dietary changes and physical activity, escalates to oral medications like metformin, and progresses to injectable therapies or insulin when blood sugar remains poorly controlled. The exact combination depends on which type of diabetes you have, how high your blood sugar runs, and how your body responds to each intervention. What makes hyperglycemia treatment more interesting than a simple checklist is how differently each layer works and why clinicians sequence them the way they do.
Why Blood Sugar Climbs in the First Place
Your body keeps blood sugar in a tight range through a feedback loop between the insulin-producing beta cells of the pancreas and the tissues that take up glucose, especially skeletal muscle and the liver. Hyperglycemia happens when that loop breaks down. In type 2 diabetes, there is a complex interplay between the body resisting insulin’s signal and the pancreas failing to produce enough insulin to compensate. Research has shown that every major subgroup of people with abnormal carbohydrate metabolism is more resistant to insulin’s action than healthy subjects, and those with more severe fasting hyperglycemia also have outright insulin deficiency.1The American Journal of Medicine. Nonketotic diabetes mellitus: Insulin deficiency or insulin resistance? Over time, chronically high blood sugar itself damages beta cells further, a phenomenon called glucose toxicity, though some of that damage is reversible when blood sugar is brought under control.2PubMed. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects
In type 1 diabetes, the immune system destroys the beta cells almost entirely, so insulin from outside the body is necessary from the start. Gestational diabetes sits somewhere in between: pregnancy hormones drive insulin resistance, and if the pancreas cannot keep up, blood sugar rises. The treatment strategy for each condition differs, but the tools overlap.
Dietary Changes as the Foundation
Diet is the first line of defense and remains relevant at every stage of treatment. The goal is not to starve yourself of carbohydrates but to control the speed and height of blood sugar spikes after meals. Two dietary strategies have strong evidence behind them: reducing carbohydrate quantity and improving carbohydrate quality.
A trial comparing a low-carbohydrate ketogenic diet against a low-glycemic-index diet in people with type 2 diabetes found that both improved blood sugar control, but the ketogenic group saw a larger drop in hemoglobin A1c (about 1.5 percentage points versus 0.5) and lost more weight (roughly 11 kg versus 7 kg).3PubMed Central. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus That said, a low-glycemic-index approach also has real benefits. A Canadian trial found that glucose tolerance declined less over a year in people eating low-glycemic-index foods compared with those on a reduced-carbohydrate diet, suggesting the quality of carbohydrates matters alongside the amount.4PubMed. Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of carbohydrates in diabetes): a randomised controlled trial
Fiber plays its own role. Viscous soluble fiber slows the movement of food through the gut, which flattens the blood sugar curve after a meal. It also feeds gut bacteria that produce short-chain fatty acids, which in turn stimulate hormones like GLP-1 that help regulate glucose.5PubMed Central. The Effects of Soluble Dietary Fibers on Glycemic Response: An Overview and Futures Perspectives Practically, this means choosing whole grains, legumes, vegetables, and fruits with edible skins over refined starches and sugary drinks.
How Exercise Lowers Blood Sugar
Physical activity acts on hyperglycemia through a mechanism that is partly independent of insulin. When your muscles contract, they pull glucose out of the bloodstream through a transporter called GLUT4 that moves to the cell surface during exercise, no insulin signal required.6PubMed. Exercise, GLUT4, and skeletal muscle glucose uptake This is why a brisk walk after a meal can visibly blunt a blood sugar spike even in someone whose body barely responds to insulin at rest.
The effects are not limited to the moment of exercise. In people with type 2 diabetes, even a single session of high-intensity exercise improved post-meal blood sugar for a full 24 hours, and a two-week program reduced average blood glucose by about 13% at 48 to 72 hours after the last workout while dramatically increasing GLUT4 expression in muscle tissue.7PubMed Central. The impact of brief high-intensity exercise on blood glucose levels Both aerobic exercise and resistance training help; guidelines typically recommend a mix, aiming for at least 150 minutes of moderate activity per week. The key practical point is that exercise works additively with diet and medication, so skipping it means you need the other tools to work harder.
Metformin and Why It Comes First
When diet and exercise are not enough to bring blood sugar to target, metformin is the drug most clinicians reach for first. It has been around for decades, is cheap, well-studied, and does not cause low blood sugar on its own. What it actually does inside the body is more complicated than it sounds. The traditional explanation is that metformin reduces the amount of glucose the liver dumps into the bloodstream, and that is true, but researchers have found it works through multiple overlapping pathways including effects in the gut.8PubMed Central. The mechanisms of action of metformin
One well-studied pathway involves metformin activating an energy-sensing enzyme in liver cells, which reduces fat production and curbs glucose output.9PubMed Central. Role of AMP-activated protein kinase in mechanism of metformin action But there is evidence that metformin also works through inhibiting certain mitochondrial processes and potentially through effects on the lysosome, and not all of its benefits can be traced to any single mechanism.10Endocrine Reviews. Cellular and Molecular Mechanisms of Metformin Action For you as a patient, the practical takeaway is that metformin lowers fasting blood sugar reliably, typically drops A1c by about 1 to 1.5 percentage points, and carries a low risk of dangerous side effects. The most common complaints are gastrointestinal: nausea, bloating, and diarrhea, which usually improve over weeks or with an extended-release formulation.
Other Oral and Injectable Medications
When metformin alone is insufficient, several medication classes can be added. Each works through a different mechanism, which is why they can be combined.
SGLT2 Inhibitors
These drugs block a transporter in the kidneys that normally reclaims glucose from urine and sends it back into the blood. By inhibiting that transporter, SGLT2 inhibitors cause you to excrete excess glucose in your urine, which lowers blood sugar while also shedding calories and some sodium.11PubMed. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors Beyond glucose control, these drugs have turned out to protect the kidneys and heart in ways that surprised researchers. The extra sodium excretion reduces blood pressure. The shift in kidney workload lowers pressure inside the kidney’s filtering units, which slows the long-term decline in kidney function. There is also evidence that SGLT2 inhibitors push the body toward a fasting-like metabolic state that may benefit the heart independently of blood sugar changes.12American Journal of Hypertension. State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications Side effects include genital yeast infections (because sugar in the urine feeds fungal growth) and, rarely, a form of diabetic ketoacidosis that can occur even at relatively normal blood sugar levels.
DPP-4 Inhibitors and Sulfonylureas
DPP-4 inhibitors work by extending the life of incretin hormones your gut releases after eating, which stimulate insulin production and suppress glucagon in a glucose-dependent way. Because their effect is linked to glucose levels, they carry a much lower risk of hypoglycemia than older drugs like sulfonylureas. A pooled analysis of randomized trials found the incidence of hypoglycemia with DPP-4 inhibitors was roughly a quarter of that seen with sulfonylureas.13PubMed. The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial A large observational study went further, finding that sulfonylureas combined with metformin were associated with about twice the risk of severe hypoglycemia and higher rates of cardiovascular events and death compared with DPP-4 inhibitors combined with metformin.14PubMed. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality Sulfonylureas still have a role because they are inexpensive and potent, but their safety profile means clinicians increasingly prefer newer alternatives when cost is not a barrier.
GLP-1 Receptor Agonists and Dual-Incretin Drugs
GLP-1 receptor agonists (like semaglutide and liraglutide) are injectable medications that mimic the incretin hormone GLP-1 but last much longer than the natural version. They stimulate insulin release when glucose is high, slow stomach emptying, reduce appetite, and promote significant weight loss. The newest generation takes this further. Tirzepatide activates both the GLP-1 and GIP receptors, and phase 3 trials showed the highest dose reduced A1c by about 2.5 percentage points and body weight by roughly 12 kg, outperforming semaglutide on both measures.15Cell Metabolism. Chasing a century of progress: The multistep discovery of multi-incretin receptor agonists For people with type 2 diabetes who have both high blood sugar and excess weight, these drugs address both problems simultaneously, which is a shift from older treatments that sometimes caused weight gain.
When Insulin Becomes Necessary
Insulin is not a last resort or a sign of failure. For people with type 1 diabetes, it is the only option from day one. For those with type 2 diabetes, it often becomes necessary as the disease progresses and beta cell function continues to decline. The modern approach to insulin therapy tries to mimic the way a healthy pancreas works: a steady background drip of insulin all day (basal), with sharp bursts around meals (bolus).
A basal-bolus regimen uses a long-acting insulin like glargine once or twice daily for the background, plus a rapid-acting insulin like lispro or aspart before each meal.16PubMed Central. A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus The dose is typically started at around 0.4 to 0.5 units per kilogram of body weight per day and then adjusted based on blood glucose readings.17Diabetes Care. Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes (RABBIT 2 Trial) Many people with type 2 diabetes start on basal insulin alone, adding mealtime doses only if targets are not met.
The speed of mealtime insulins has improved dramatically. The newest ultra-rapid formulations appear in the bloodstream in about 2.5 minutes and begin working within 20 to 30 minutes, compared with about 5 minutes and slightly later onset for previous rapid-acting insulins.18Clinical Diabetes. Ultra-Rapid-Acting Insulins: How Fast Is Really Needed? This faster action better matches the blood sugar spike that follows a meal, reducing both post-meal highs and late-onset low blood sugar.
How Insulin Has Changed Over a Century
The insulin injected into the first human patient in 1922 was a crude extract from animal pancreas, full of impurities that caused painful reactions. Over the following decades, purification improved gradually. The breakthrough came in the 1980s when recombinant DNA technology made it possible to produce human insulin synthetically in unlimited quantities. By the mid-1990s, designer insulins known as analogs arrived, starting with lispro in 1996, followed by aspart and glulisine.19PubMed. One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs These analogs were engineered to absorb faster from under the skin, better controlling post-meal glucose and lowering the risk of hypoglycemia that plagued older formulations.20PubMed Central. Insulin: evolution of insulin formulations and their application in clinical practice over 100 years This trajectory matters because it explains why insulin therapy today is more precise and more flexible than even a generation ago.
Treating Hyperglycemia in the Hospital
When you are hospitalized for surgery, infection, or another acute illness, blood sugar often spikes even if your diabetes is well controlled at home. Stress hormones, IV fluids containing dextrose, and changes to your usual routine all contribute. The old approach, still used in some settings, is sliding-scale insulin: you get a reactive dose of short-acting insulin based on your current blood sugar reading, with no scheduled background insulin.
The evidence is clear that this approach is inferior. A meta-analysis of randomized trials found that scheduled basal-bolus insulin lowered average daily blood glucose by 14 to 29 mg/dL more than sliding-scale regimens.21PubMed. Efficacy of basal-bolus insulin regimens in the inpatient management of non-critically ill patients with type 2 diabetes: A systematic review and meta-analysis In a study of patients admitted for orthopedic surgery, those managed with basal-bolus insulin had fewer complications overall, fewer infections, and shorter hospital stays compared with those on sliding-scale protocols.22PubMed. Nurse-managed basal-bolus versus sliding-scale insulin regimen in subjects with hyperglycemia at admission for orthopedic surgery: a propensity score approach The tradeoff is a modestly higher rate of mild hypoglycemia with basal-bolus therapy, though severe low blood sugar remains uncommon with either approach.21PubMed. Efficacy of basal-bolus insulin regimens in the inpatient management of non-critically ill patients with type 2 diabetes: A systematic review and meta-analysis
Hyperglycemic Emergencies
Sometimes hyperglycemia escalates into a life-threatening crisis. The two main emergencies are diabetic ketoacidosis (DKA), where the body burns fat so aggressively that toxic acids build up, and hyperosmolar hyperglycemic state (HHS), where blood sugar climbs extremely high and the body becomes severely dehydrated without significant ketone production. Both require emergency room treatment.
The treatment protocol for both conditions centers on three pillars: aggressive IV fluids, intravenous insulin, and electrolyte replacement, especially potassium.23PubMed Central. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State Fluid resuscitation alone can lower blood sugar by roughly 50 to 70 mg/dL per hour even before insulin is started, because restoring circulation helps the kidneys excrete glucose and brings down stress hormones that were driving sugar production.24Diabetes Care. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report In HHS specifically, guidelines recommend starting insulin only once the drop in blood osmolality from fluids has plateaued, unless the patient also has significant ketones, in which case insulin begins immediately alongside fluids.25PubMed Central. Management of Hyperosmolar Hyperglycaemic State (HHS) in Adults: An updated guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care Group Blood sugar monitoring happens every one to two hours, and electrolytes are rechecked every four hours until the crisis resolves.
Managing Hyperglycemia During Pregnancy
Gestational diabetes carries unique stakes because high blood sugar affects both the mother and the developing baby, raising the risk of a large-for-gestational-age infant, birth injuries, and neonatal metabolic problems. The first-line approach is dietary counseling focused on the type, amount, and timing of carbohydrate intake, along with physical activity to improve insulin sensitivity.26PubMed Central. Diet and Healthy Lifestyle in the Management of Gestational Diabetes Mellitus
A randomized trial found that a low-glycemic-index diet cut the proportion of women who ultimately needed insulin roughly in half: 29% in the low-GI group versus 59% in the higher-GI group. Of those in the higher-GI group who qualified for insulin, nearly half were able to avoid it by switching to a low-GI diet.27Diabetes Care. Can a Low–Glycemic Index Diet Reduce the Need for Insulin in Gestational Diabetes Mellitus?: A randomized trial When diet alone is not enough, insulin is the standard add-on. A trial of over 200 women with impaired glucose tolerance during pregnancy found that routine insulin treatment did not improve outcomes over diet alone in those with mild carbohydrate intolerance, though about 14% of the diet-only group eventually needed insulin when their blood sugar exceeded acceptable thresholds.28Diabetes. Gestational Diabetes Mellitus (GDM): Comparative Evaluation of Two Treatment Regimens, Diet Versus Insulin and Diet The practical lesson is that frequent self-monitoring guides the decision to escalate treatment, rather than adding insulin automatically for every woman with gestational diabetes.
The Hypoglycemia Tradeoff With Intensive Treatment
Every treatment that lowers blood sugar carries some risk of pushing it too low, and that risk increases as you tighten control. This is especially relevant for people on insulin or sulfonylureas. What makes it more insidious is that intensive insulin therapy can blunt your body’s natural alarm system. Research in people with type 1 diabetes found that after a period of tight insulin pump therapy, the hormonal responses that normally kick in during a low (epinephrine, growth hormone, cortisol) were significantly reduced, meaning the body mounted a weaker defense against falling blood sugar and the person felt fewer warning symptoms.29PubMed. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes
This condition, known as hypoglycemia unawareness, is reversible. Studies have shown that carefully relaxing glucose targets for a period can restore both the hormonal response and the subjective feeling of low blood sugar, allowing safer return to tighter control later.30PubMed. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM For clinicians and patients alike, this means the best blood sugar target is not always the lowest achievable one. The target should balance the long-term benefits of tight control against the immediate danger of recurrent lows, and it should be revisited regularly.
Continuous Glucose Monitors and Automated Insulin Delivery
Technology has changed how hyperglycemia is managed day to day. Continuous glucose monitors (CGMs) provide a glucose reading every few minutes without finger sticks, and when paired with an insulin pump, they form a closed-loop or “artificial pancreas” system that adjusts insulin delivery automatically. A key metric in this space is time in range, the percentage of the day your blood sugar stays between 70 and 180 mg/dL. In a hospital feasibility trial of automated insulin delivery, participants achieved an average time in range of about 68%, with very little time spent dangerously low.31PubMed Central. Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multicenter, Single-Arm, Feasibility Trial
One nuance worth knowing: time in range is not a single number. When researchers applied tighter glucose targets during nighttime hours, the apparent time in range dropped significantly, by about 8 percentage points on average.32PubMed Central. Time in Range Analysis in Automated Insulin Delivery Era: Should Day and Nighttime Targets be the Same? This matters if you are comparing your own CGM results against benchmarks: make sure you know whether the target window is the same. For most people with type 1 or type 2 diabetes, getting above 70% time in range on a standard 70-180 mg/dL window represents solid glucose management.
When Eating Matters as Much as What You Eat
An emerging line of research suggests that when you eat influences blood sugar independently of what you eat. Time-restricted eating, where you consume all your food within a defined window, has shown metabolic benefits in both prediabetes and normal glucose tolerance. A controlled inpatient study found that eating all meals between 10 a.m. and 5 p.m. led to lower 24-hour glucose levels compared with spreading the same calories over a window from 7 a.m. to 9 p.m., with the improvement driven mainly by lower overnight glucose.33Endocrine Reviews. Time-restricted Eating for the Prevention and Management of Metabolic Diseases More broadly, eating earlier in the day tends to be associated with better glucose tolerance and a higher thermic effect of food compared with eating the same meals later. This does not mean skipping dinner is a prescription for everyone, but it does suggest that a late-night eating pattern may make hyperglycemia harder to control.
Metabolic Surgery and Diabetes Remission
For people with type 2 diabetes and severe obesity, bariatric (metabolic) surgery can produce dramatic improvements in blood sugar, sometimes within days of the procedure, well before any meaningful weight loss has occurred. Roux-en-Y gastric bypass, for instance, typically results in a 35% to 40% loss of baseline body weight and leads to diabetes remission in a substantial fraction of patients.34Diabetes & Metabolism Journal. A Gut Feeling to Cure Diabetes: Potential Mechanisms of Diabetes Remission after Bariatric Surgery The speed of improvement strongly suggests that the mechanism is not simply about losing fat. Rerouting food through the gut changes the release of incretin hormones, alters bile acid signaling, shifts the gut microbiome, and may improve beta cell function directly.35PubMed Central. Mechanisms Underlying Type 2 Diabetes Remission After Metabolic Surgery Surgery is not appropriate for everyone and carries its own risks, but for the right candidate it can reduce or eliminate the need for diabetes medications in a way that no pill or injection currently matches.